SEARCH

SEARCH BY CITATION

Introduction

  1. Top of page
  2. Introduction
  3. Subjects and Methods
  4. Results
  5. Discussion
  6. REFERENCES
  7. APPENDIX A:
  8. APPENDIX B:

Scleroderma (systemic sclerosis [SSc]) is a rare connective tissue disease with variable involvement of the skin and major organs (1). The hallmarks are fibrosis, vascular instability, and, initially, inflammation. The prevalence of SSc may be as high as 2 of 10,000 (2), but SSc is far less common than rheumatoid arthritis (RA; 0.8%) and systemic lupus erythematosus (0.2%) (3, 4). Therefore, rheumatologists who do not have a specific interest in SSc will rarely treat individuals with this condition. Although there is no strong evidence for effective disease-modifying treatment for SSc (in particular, well-designed randomized controlled trials [RCTs] of early diffuse SSc have been negative &lsqbr;5, 6&rsqbr;), disease management may be achieved through the treatment of associated organ involvement. However, treatments for most organ involvement have shown no significant increase in survival in prospective studies, with the exception of aggressive treatment of SSc renal crisis treated with angiotensin-converting enzyme inhibitors and possibly therapy of pulmonary arterial hypertension (PAH) with prostacyclin and endothelin receptor blocker medications (7, 8). Standard therapies for gastroesophageal reflux disease (GERD; such as proton-pump inhibitors), gastric dysmotility (promotility agents), and Raynaud's phenomenon (calcium-channel blockers) are used.

The rarity of the disease, the clinical heterogeneity, and the lack of effective agents to date render therapy a major challenge. There are currently no widely disseminated therapeutic guidelines for the management of scleroderma. The present qualitative survey study was designed to provide a general synopsis of the current standard of care for patients with SSc treated by general rheumatologists and those with an interest in scleroderma. The objective was to assess whether rheumatologists in North America (defined as all practicing members of the Canadian Rheumatology Association [CRA] and randomly selected members of the American College of Rheumatology [ACR] practicing in the US, exclusive of those also in the CRA) demonstrated similar prescribing/treatment practices for their patients with SSc compared with Scleroderma Clinical Trials Consortium (SCTC) members, and to relate treatment trends to published evidence. Thus, this research was hypothesis generating and was meant to establish a starting point from which future research on standard treatment for SSc could be developed, providing a “snap shot” of scleroderma treatment practices. We hypothesized that SCTC members would treat patients with SSc differently (compared with non-SSc expert rheumatologists) because they would be more aware of published and unpublished results of clinical trials. In other therapeutic areas, there are opinion leaders (perhaps fast adapters) who treat patients more aggressively (such as treatment in RA targeting a low disease activity score) (9).

Subjects and Methods

  1. Top of page
  2. Introduction
  3. Subjects and Methods
  4. Results
  5. Discussion
  6. REFERENCES
  7. APPENDIX A:
  8. APPENDIX B:

A 5-page, self-administered survey was designed to assess the number of limited and diffuse patients with SSc followed; frequency and type of therapies for disease manifestations overall and for involvement of internal organs such as gastrointestinal tract, kidneys, lungs, heart, joints, muscles, and pulmonary arteries; and physicians' estimates of comorbidity and mortality frequencies in their patients with SSc. The questionnaire was mailed to 302 members of the CRA, a random subset of 312 members of the ACR, and 139 members of the SCTC. The random subset of ACR members was drawn using the ACR 2002 Directory. The directory was opened to a random page and every twentieth member (excluding those with non-US addresses) was chosen to obtain a sample size similar to that of the CRA. Physicians who followed <3 patients with SSc and those only in research were excluded from subsequent analyses.

The SCTC is an incorporated not-for-profit organization of scleroderma researchers particularly interested in research in the conduct and methodology of therapeutic trials in scleroderma. The SCTC is an international group of scleroderma researchers whose mandate is to advance the state of knowledge and therapeutic practices for scleroderma through clinical research trials. Membership occurs via the institution (SCTC members are affiliated with an academic institution) and requires that member institutions have a dedicated scleroderma clinic, have participated in at least 1 SSc clinical trial, and have published at least 1 SSc report in the past 5 years. Provisional membership can be attained for institutions that do not meet all requirements (10). The SCTC is multinational, but the largest membership representation is from the US. We considered the members of the SCTC as scleroderma treatment experts for the purposes of this study. Half of the CRA members are academic based, and we are unaware of the proportion of surveyed ACR members who were affiliated with academic centers (due to a high nonresponse rate).

The questionnaire began with a short demographics section (age, sex, year and location of rheumatology fellowship, location of practice and other subspecialties) followed by a section on patient characteristics (annual number of limited and diffuse patients with SSc seen). Questions 10–18 comprised pages 2–4, and each question was of the format, “How often do you use the following for (e.g., worsening interstitial lung disease [ILD]) in scleroderma?” A list of applicable therapies was provided with checkoff boxes under the options “Never,” “Rarely,” “Occasionally,” and “Frequently” (Appendix A). Survey respondents were instructed to select all options that applied. On the final page respondents were asked to indicate what percentage of their patients with SSc had comorbidities that were presented in a list, with check-box options for proportion ranges (Appendix B). The last formal question (question 20) asked physicians to report the frequencies of various causes of mortality (e.g., “Other causes, with scleroderma a significant comorbidity”), choosing from the same frequency categories used for questions 10–18.

The questionnaire was pretested on the 4 rheumatologists in our institution who were not involved in the development of the study survey. No major revisions were required. Responses to the questionnaire were not validated.

The intial survey was sent via postal mail with a stamped return envelope or international reply coupons for overseas SCTC members. Survey nonrespondents were re-sent the questionnaire by facsimile (with instructions to return by facsimile) one additional time. If subjects did not send their completed questionnaires back after the second request, they were considered nonrespondents.

Data were entered into a JMP statistical software (11) database using a standardized template based on the study questionnaire. Ambiguous responses were coded based on agreement by the 2 authors responsible for data entry, and if no agreement could be reached, the particular question was considered a nonresponse item. Data were verified by reentering a subset of randomly chosen surveys. Between-groups comparisons (SCTC compared with both CRA and ACR) were performed for reported value frequencies using proportion statistical tests. P values for the SCTC versus CRA and SCTC versus ACR were reported together unless they differed in significance.

Interpretation of data coding categories

Due to small numbers of observations in each category of response (“never,” “rarely,” “occasionally,” and “frequently”), data fields were combined in the final analysis to allow for statistical inference testing using contingency tables. For the majority of questions, comparisons were made across physician groups (SCTC, CRA, and ACR) regarding whether they currently use a treatment (i.e., the respondent answered that he or she used that treatment “rarely,” “occasionally,” or “frequently”) versus never use. Comprehensive data on physician-reported frequency of use were also presented for treatments that were used by ≥80% of respondents in all groups (SCTC, CRA, and ACR) and also for methotrexate (MTX) and D-penicillamine for the treatment of skin involvement (despite not being used by ≥80% of respondents), demonstrating that frequent use was relatively uncommon.

Results

  1. Top of page
  2. Introduction
  3. Subjects and Methods
  4. Results
  5. Discussion
  6. REFERENCES
  7. APPENDIX A:
  8. APPENDIX B:

The SCTC, CRA, and ACR response rates to the survey were 56%, 48%, and 19%, respectively. Baseline characteristics are shown in Table 1. The SCTC saw more patients with SSc per year and during training than the ACR or CRA (SCTC was currently seeing 93 patients with scleroderma annually versus 14 in the CRA and 17 in the ACR; P < 0.005). Prescribing practices are presented in Table 2 (drug use versus never use) and Table 3 (frequent use versus all other options).

Table 1. Baseline characteristics of the rheumatologists surveyed*
CharacteristicSCTC (n = 139)CRA (n = 302)ACR (n = 312)P
  • *

    SCTC = Scleroderma Clinical Trials Consortium; CRA = Canadian Rheumatology Association; ACR = American College of Rheumatology; vs = versus; SSc = systemic sclerosis.

  • P values of SCTC versus CRA and SCTC versus ACR that were statistically significant.

  • Specialties practiced were mainly internal medicine or pediatric rheumatology.

Respondents, no. (%)78 (56)146 (48)59 (19)
Age, mean ± SEM years49 ± 148 ± 0.849 ± 1.00.91
Women, %3434280.66
Clinical practice (vs. clinical practice and research), no. (%)14 (19)89 (64)41 (77)0.0001
Practicing other specialty besides rheumatology, no. (%)20 (26)44 (31)15 (26)0.69
Time after rheumatology fellowship completed, mean ± SEM years16 ± 117 ± 115 ± 10.40
SSc patients seen per year, mean ± SEM93 ± 1814 ± 217 ± 20.005
SSc patients seen during training, mean ± SEM69 ± 724 ± 643 ± 90.0001
Estimate of SSc in practice with diffuse disease, %40 ± 236 ± 240 ± 30.26
Table 2. Prescribing practices in SSc*
 RCT evidence for treatment in SSc (reference)SCTC (n = 78)CRA (n = 146)ACR (n = 59)P
  • *

    Data indicate the percentage of respondents who reported that they currently “use” the drugs (inclusive of categories “frequently,” “occasionally,” and “rarely”). P values were for the comparison of “use” versus “never use” the drugs, and were for the SCTC versus each other group (CRA and ACR). RCT = randomized controlled trial; N = number of RCTs; weak = weak trial and/or possible effect; neg = negative trial; NSAIDs = nonsteroidal antiinflammatory drugs; anti–TNF = anti–tumor necrosis factor; pos = positive trial; ACE = angiotensin-converting enzyme; SSRI = selective serotonin reuptake inhibitors; PAH = pulmonary arterial hypertension; see Table 1 for additional definitions.

  • Unstable estimate.

  • P value for SCTC versus CRA.

Skin disease     
 MethotrexateN = 2; weak (6, 11)8575620.20
 D-penicillamineN = 1; neg. (5)6176700.12
 Steroids 7572610.10
Joint involvement     
 NSAIDs 9799980.63
 Prednisone 9188880.77
 Methotrexate 9488860.30
Myositis     
 Prednisone 99951000.22
 Methotrexate 9389900.75
 Azathioprine 7354550.03
Interstitial lung disease     
 CyclophosphamideRCTs pending9983930.001
 D-penicillamine 1739320.03
 Steroids ([UPWARDS ARROW] dose) 8685820.90
 Azathioprine 7855670.01
 Anti–TNF 19450.005
Raynaud's phenomenon     
 Calcium-channel blockersN = 8; pos. moderate effect (18)100991000.48
 ACE inhibitorsN = 1; weak (19)8165750.06
 Surgical sympathectomy 8372740.29
 IloprostN = 9; pos. (19–21)8465400.0001
 SSRIN = 1; weak (23)4818360.0001
Digital ulcers     
 Antibiotics 9276930.006
 Antiplatelet agents 8984920.33
 Pentoxifylline 6872760.67
 Steroids ([UPWARDS ARROW] dose) 3039300.36
 IloprostN = 3; pos. (19, 21)8160370.0001
 BosentanN = 1; pos. (22)4012270.0003
PAH     
 Anticoagulants 98100950.5
 BosentanN = 2; pos. (8, 36, 37)8370790.5
 EpoprostenolN = 1; pos. (38)7652610.16
 TreprostinilN = 1; pos-weak (39)285180.1
 IloprostN = 1; weak (40)7147290.008
Table 3. Frequency of use of treatments commonly used (defined as use by ≥80% of total respondents) to treat SSc manifestations reported by SCTC, CRA, and ACR members*
ManifestationSCTC (n = 78)CRA (n = 146)ACR (n = 59)P
  • *

    Values are the percentage unless otherwise indicated. NSAIDs = nonsteroidal antiinflammatory drugs; see Table 1 for additional definitions.

  • P values are for dichotomized comparisons of “Frequent use” versus all other options (inclusive of categories “Occasionally,” “Rarely,” and “Never”) among physician groups (SCTC compared with CRA and ACR).

  • Denotes a P value for SCTC versus CRA.

  • §

    Denotes a P value for SCTC versus ACR.

Skin involvement    
 Methotrexate    
  Frequently2722140.30
  Occasionally334033 
  Rarely251414 
  Never152538 
 D-penicillamine    
  Frequently1220120.24
  Occasionally313312 
  Rarely242321 
  Never292428 
 Steroids    
  Frequently9920.37
  Occasionally343724 
  Rarely312734 
  Never252839 
Joint involvement    
 Methotrexate    
  Frequently4136320.68
  Occasionally363735 
  Rarely171519 
  Never61214 
 Prednisone    
  Frequently2724210.77
  Occasionally454044 
  Rarely192323 
  Never91212 
 NSAIDs    
  Frequently7461600.16
  Occasionally172933 
  Rarely695 
  Never312 
Myositis    
 Methotrexate    
  Frequently4732280.08
  Occasionally374452 
  Rarely91110 
  Never71110 
 Prednisone    
  Frequently7151480.01
  Occasionally243440 
  Rarely31012 
  Never150 
Interstitial lung disease    
 Cyclophosphamide    
  Frequently773032< 0.0001
  Occasionally173941 
  Rarely41420 
  Never1177 
 Steroids ([UPWARDS ARROW] dose)    
  Frequently3243200.15
  Occasionally262748 
  Rarely281515 
  Never141518 
Raynaud's phenomenon    
 Calcium-channel blockers    
  Frequently9485950.06
  Occasionally4145 
  Rarely1101.0§
  Never000 
Digital ulcers    
 Antiplatelet agents    
  Frequently5627300.0003
  Occasionally202730 
  Rarely1221200.01§
  Never11168 

Drug use (including frequent, occasional, and rare use) versus never use

Drug use versus never use was similar between groups for the majority of agents used for skin and joint manifestations. The most commonly used agents (by all rheumatology groups overall) for joint involvement were nonsteroidal antiinflammatory drugs (99.9%), MTX (90%), and prednisone (89%). Seventy-six percent of physicians overall used MTX for skin involvement. However, of those who reported using MTX, only 22% (27% SCTC, 22% CRA, and 14% ACR; P = 0.30) used it frequently. D-penicillamine was used for skin involvement by 70% of respondents, but only 16% reported using it frequently (12% SCTC, 20% CRA, and 12% ACR; P = 0.24).

To treat myositis, all rheumatology groups used (frequently, occasionally, or rarely) prednisone (99.8%) and MTX (91%), with no differences among groups. However, SCTC members were more apt to use azathioprine for myositis (P = 0.03). SCTC members were also more likely to use iloprost for Raynaud's phenomenon (84% versus 65% CRA and 40% ACR; P = 0.0001), iloprost for digital ulcers (81% versus 60% CRA and 37% ACR; P = 0.0001), and bosentan for digital ulcers (40% versus 12% CRA and 27% ACR; P = 0.0003) than either CRA or ACR members. SCTC members were more likely than CRA members (but not ACR members) to use selective serotonin reuptake inhibitors (SSRIs) for Raynaud's phenomenon (48% versus 18% CRA and 36% ACR; P = 0.0001) and antibiotics for digital ulcers (92% versus 76% CRA and 93% ACR; P = 0.006). Results are summarized in Table 2.

Treatment of ILD was variable between groups: SCTC members were more likely than CRA members (but not ACR members) to use cyclophosphamide (99% versus 83% CRA and 93% ACR; P < 0.001) and azathioprine (78% versus 55% CRA and 67% ACR; P = 0.01), and were more likely than both CRA and ACR members to use anti–tumor necrosis factor (anti–TNF) drugs (19% versus 4% CRA and 5% ACR; P = 0.005). However, SCTC members were less likely to use D-penicillamine for ILD (17% versus 39% CRA and 32% ACR; P = 0.03). High-dose steroids were used similarly between groups (Table 2).

Frequent use versus all other options (occasional, rare, and never use)

Frequent use of many drugs, including all drugs for skin disease, was reported by <27% of rheumatologists in any group. SCTC members were more likely than CRA or ACR members to use prednisone for myositis (P = 0.01), cyclophosphamide for ILD (P < 0.0001), and antiplatelet agents for digital ulcers (P = 0.0005) (Table 3).

Pulmonary arterial hypertension and gastroesophageal reflux disease

The SCTC members were more likely to treat PAH (58% versus 17% CRA and 45% ACR; P < 0.0001). The most commonly used agents (for all rheumatology groups overall) were anticoagulants (98%), bosentan (79%), and epoprostenol (66%). ACR members were less likely than CRA and SCTC members to frequently use anticoagulants (26% versus 70% and 72%, respectively; P = 0.003). SCTC members were more likely to use (occasionally or rarely) treprostinil (28% versus 5% CRA and 18% ACR; P = 0.01), but none reported frequent use. With respect to GERD, proton-pump inhibitors and promotility agents were prescribed very frequently by all groups, with no differences among groups (P = 0.50 and P = 0.74, respectively). Eighteen percent of CRA members (versus 3% SCTC and 5% ACR; P = 0.006) never used H2 blockers.

Frequency of disease manifestations and causes of mortality in SSc

Respondents were asked to indicate the percentage of their patients with SSc who demonstrated disease manifestations that could be associated with SSc (see Appendix B). The frequency of disease manifestation estimates varied between the groups (but only slightly), with SSc experts reporting a higher frequency of ILD, PAH, small bowel overgrowth, and erectile dysfunction in their patients than CRA and ACR members. Physicians' estimates of comorbidity and mortality frequencies are presented in Tables 4 and 5.

Table 4. Physicians' estimates of frequency of comorbidity in patients with SSc*
ComorbiditySCTCCRAACR
  • *

    See Table 1 for definitions.

Small bowel overgrowth   
 <5%214641
 5–10%433440
 11–20%221312
 21–30%1035
 >30%342
Interstitial lung disease  
 <5%1614
 5–10%72619
 11–20%223316
 21–30%291935
 >30%401616
Renal crisis  
 <5%487470
 5–10%381423
 11–20%1175
 21–30%152
 >30%000
Pulmonary arterial hypertension  
 <5%133021
 5–10%273035
 11–20%272626
 21–30%271112
 >30%627
Cardiomyopathy  
 <5%416749
 5–10%442240
 11–20%1187
 21–30%132
 >30%102
Inflammatory arthritis  
 <5%14107
 5–10%303332
 11–20%312226
 21–30%142323
 >30%101312
Depression  
 <5%10170
 5–10%222012
 11–20%102223
 21–30%302335
 >30%271630
Erectile dysfunction  
 <5%366247
 5–10%222124
 11–20%71012
 21–30%1549
 >30%2049
Table 5. Physicians' estimates of frequency of causes of mortality in patients with SSc*
Causes of mortalitySCTC (n = 78)CRA (n = 146)ACR (n = 59)P
  • *

    Values are the percentage unless otherwise indicated. P values provided for between groups (SCTC versus CRA, ACR) differences for reports of causal factors that were frequent versus occasional, rare, or never. Data were collapsed to conduct statistical inference testing with stable chi-squared statistics. PAH = pulmonary arterial hypertension; see Table 1 for additional definitions.

SSc-related renal involvement    
 Frequently6750.96
 Occasionally353314 
 Rarely554759 
 Never31322 
SSc-related heart involvement    
 Frequently17650.05
 Occasionally442725 
 Rarely443938 
 Never21214 
SSc-related lung fibrosis    
 Frequently4627250.02
 Occasionally434958 
 Rarely101918 
 Never060 
SSc-related PAH    
 Frequently4628130.001
 Occasionally424871 
 Rarely101916 
 Never160 
Other causes with SSc a significant comorbidity    
 Frequently5742410.13
 Occasionally394356 
 Rarely3133 
 Never020 
Other causes    
 Frequently2430300.71
 Occasionally604458 
 Rarely16189 
 Never073 

Discussion

  1. Top of page
  2. Introduction
  3. Subjects and Methods
  4. Results
  5. Discussion
  6. REFERENCES
  7. APPENDIX A:
  8. APPENDIX B:

Several observations from this study are notable when considered in the context of the SSc evidence–based literature. One such observation is that 70% of respondents reported ever using D-penicillamine for skin involvement, but only 16% reported using it frequently (12% SCTC, 20% CRA, and 12% ACR; P = 0.24) (Tables 2 and 3). Even this level of use is interesting considering that a negative trial exists in early diffuse scleroderma (5). Another notable observation, given that the results of clinical trials do not show a clear beneficial effect of MTX (6, 12), is that 76% of physicians overall used MTX for skin involvement; however, only 22% (27% SCTC, 22% CRA, and 14% ACR; P = 0.30) used it frequently (Tables 2 and 3).

Treatment of ILD with cyclophosphamide was variable between groups, but was high for all groups (i.e., >83% for all; P < 0.001) (Table 2). This use is relatively consistent with the evidence where positive anecdotal data exist (and 2 ongoing trials) (13–17). It is also interesting that SCTC members were more likely than CRA members (but not ACR members) to use azathioprine (P = 0.01), and were more likely than both CRA and ACR members to use anti–TNF drugs (P = 0.005) (Table 2); no RCTs or published reports exist concerning this finding.

With respect to Raynaud's phenomenon, all groups used calcium-channel blockers, consistent with positive published trials in the literature (18). SCTC members were also more likely than either the CRA or ACR members to use iloprost for Raynaud's phenomenon (P = 0.0001) and for digital ulcers (P = 0.0001) (Table 2), where positive trial evidence has been published for both Raynaud's phenomenon (19–21) and digital ulcers (19, 21). SCTC members also were more likely than CRA or ACR members to use bosentan for digital ulcers (P = 0.0003) (Table 2), where there is one recently published trial of bosentan for the prevention of digital ulcers (it was not published at the time of the survey) (22). SCTC members were more likely than CRA members (but not ACR members) to use SSRIs for Raynaud's phenomenon (P = 0.0001) and antibiotics for digital ulcers (P = 0.006). There is one positive trial for SSRIs in Raynaud's phenomenon that included idiopathic cases as well as those secondary to SSc (23). No RCTs for antibiotics in digital ulcers secondary to SSc have been conducted.

SCTC members were more likely than CRA or ACR members to treat PAH (58%, 17%, and 45%, respectively; P < 0.0001). Anticoagulants were used by 98% of all physicians combined, but ACR members were less likely than CRA and SCTC members to frequently use anticoagulants (26%, 70%, and 72%, respectively; P = 0.003). A positive association with anticoagulant use and survival has been demonstrated using controlled retrospective data only in primary pulmonary hypertension; however, PAH associated with SSc is often treated similarly to idiopathic PAH, where anticoagulation is standard therapy (24). Although SCTC members were more likely to use (occasionally or rarely) treprostinil (P = 0.01), this medication was not approved in Canada at the time of this survey.

The use of self report of treatment practices and estimated patient frequencies in this study allows the potential for recall bias and measurement error. There was no confirmatory review of medical records to determine the accuracy of answers. We are unaware of any rheumatologic study comparing and validating physician response using actual medical records. One could assume that physicians may overreport best possible care. The response rate was low and there is possibly nonresponse bias (i.e., respondents may be different from the nonrespondents). Self-selection bias may have been present, particularly in the ACR sample where the response rate was low (19%). Respondents to the survey may have had opinions that were not representative of all ACR (or other organization) members, and this should be considered when interpreting survey results. Recall bias while reporting the number of patients with SSc seen during fellowship training certainly occurred due to the long time lag; however, we were interested in the paucity of patients with SSc seen by many trainees in the SCTC, CRA, and ACR (mean ± SEM 69 ± 7, 24 ± 6, and 43 ± 9, respectively).

There is likely a referral bias whereby scleroderma experts see more severe disease or may recognize organ involvement more often, or both. The SCTC members were likely better able to answer how many patients they see annually because many have SSc databases, whereas CRA and ACR members may be less likely to have these databases. Members of the CRA were least likely to use TNF inhibitors in SSc. There were some differences in the treatment of SSc between Canada, the US, and the SCTC, perhaps due to the lack of guidelines and proven interventions. The differences in treating SSc between SCTC members and the other study groups (CRA and ACR) may be confounded by the sample selection (or nonresponse error), as 19% of SCTC members were in clinical practice only (with no research) compared with ∼64% of CRA members and 77% of ACR respondents. Therefore, SCTC members with research-based practices may be more likely to have access to even unpublished SSc literature. However, in most cases the usual response for disease modification therapies was “no treatment,” which supports the lack of positive literature in randomized trials. Interestingly, D-penicillamine is at times still used for skin in scleroderma despite a negative trial in early diffuse scleroderma (5).

An additional limitation of this study was that because this was a cross-sectional study meant to represent a current overview of prescribing trends in the treatment of SSc, it was beyond the scope of our research to assess how physicians' treatment styles change over time in response to new information in the medical literature. We do not know why someone does or does not prescribe a certain drug. Validation of the study responses was also beyond the scope of this study. The poor response rates make generalization to all members of the organizations problematic.

We conclude that scleroderma experts see more patients with SSc and use more immunosuppressives, including unproven treatments. Scleroderma experts may treat more severe cases, but it also may be that ILD and PAH are underrecognized by nonexperts. Erectile dysfunction (25–30) and depression (31–35) seem to be frequent problems in scleroderma, each with a substantial impact on patients, and this has been reported in the literature. Guidelines for the evidence-based treatment of scleroderma are needed to help unify treatment and establish screening for organ involvement, particularly for nonexperts, where effective treatment is known. The systematic dissemination of clinical trial results will be ever more important as several randomized trials will soon be reported, including 3 in ILD (2 with cyclophosphamide, 1 with bosentan) and 1 in healing of digital ulcers with bosentan. Other randomized trials, including high-dose cyclophosphamide versus stem cell transplant in diffuse scleroderma, are recruiting subjects. The data from these trials will undoubtedly help standardize scleroderma treatment, especially if results are positive.

REFERENCES

  1. Top of page
  2. Introduction
  3. Subjects and Methods
  4. Results
  5. Discussion
  6. REFERENCES
  7. APPENDIX A:
  8. APPENDIX B:
  • 1
    Medsger TA Jr. Systemic sclerosis (scleroderma), eosinophilic fasciitis, and calcinosis. In: McCartyDJ, editor. Arthritis and allied conditions. Philadelphia: Lea and Febiger; 1985.
  • 2
    Thompson AE, Pope JE. Increased prevalence of scleroderma in southwestern Ontario: a cluster analysis. J Rheumatol 2002; 29: 186773.
  • 3
    Maini R, Zvaifler N. Rheumatoid arthritis and other synovial disorders. In: KlippelJ, DieppeP, editors. Rheumatology. Philadelphia: Mosby; 1998. Section 5: 2.16.
  • 4
    Ward MM. Prevalence of physician-diagnosed systemic lupus erythematosus in the United States: results from the third national health and nutrition examination survey. J Womens Health (Larchmt) 2004; 13: 7138.
  • 5
    Clements PJ, Furst DE, Wong WK, Mayes M, White B, Wigley F, et al. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum 1999; 42: 1194203.
  • 6
    Pope JE, Bellamy N, Seibold JR, Baron M, Ellman M, Carette S, et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001; 44: 13518.
  • 7
    De la Mata J, Gomez-Sanchez MA, Aranzana M, Gomez-Reino JJ. Long-term iloprost infusion therapy for severe pulmonary hypertension in patients with connective tissue diseases. Arthritis Rheum 1994; 37: 152833.
  • 8
    Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension [published erratum appears in N Engl J Med 2002;346:1258]. N Engl J Med 2002; 346: 896903.
  • 9
    Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004; 364: 2639.
  • 10
    Scleroderma Clinical Trials Consortium. Membership information. URL: http://www.sctc-online.org/membersh.htm.
  • 11
    JMP statistical software, version 4. Cary (NC): SAS Institute; 2000.
  • 12
    Van den Hoogen FH, Boerbooms AM, Swaak AJ, Rasker JJ, van Lier HJ, van de Putte LB. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol 1996; 35: 36472.
  • 13
    Akesson A. Cyclophosphamide therapy for scleroderma. Curr Opin Rheumatol 1998; 10: 57983.
  • 14
    Calguneri M, Apras S, Ozbalkan Z, Ertenli I, Kiraz S, Ozturk MA, et al. The efficacy of oral cyclophosphamide plus prednisolone in early diffuse systemic sclerosis. Clin Rheumatol 2003; 22: 28994.
  • 15
    Mittal G, Udwadia Z, Joshi VR. Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis [letter]. J Rheumatol 2003; 30: 11212.
  • 16
    Griffiths B, Miles S, Moss H, Robertson R, Veale D, Emery P. Systemic sclerosis and interstitial lung disease: a pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function. J Rheumatol 2002; 29: 23718.
  • 17
    Denton CP. Personal communication to Dr. Janet Pope, February 2005.
  • 18
    Thompson AE, Shea B, Welch V, Fenlon D, Pope J. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis. Arthritis Rheum 2001; 44: 18417.
  • 19
    Janini SD, Scott DG, Coppock JS, Bacon PA, Kendall MJ. Enalapril in Raynaud's phenomenon. J Clin Pharm Ther 1988; 13: 14550.
  • 20
    Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells G, et al. Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev 2000:CD000953.
  • 21
    Scorza R, Caronni M, Mascagni B, Berruti V, Bazzi S, Micallef E, et al. Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon: a randomized, controlled study. Clin Exp Rheumatol 2001; 19: 5038.
  • 22
    Korn JH, Mayes M, Matucci Cerinic M, Rainisio M, Pope J, Hachulla E, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004; 50: 398593.
  • 23
    Coleiro B, Marshall SE, Denton CP, Howell K, Blann A, Welsh KI, et al. Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology (Oxford) 2001; 40: 103843.
  • 24
    Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327: 7681.
  • 25
    Hong P, Pope JE, Ouimet JM, Rullan E, Seibold JR. Erectile dysfunction associated with scleroderma: a case-control study of men with scleroderma and rheumatoid arthritis. J Rheumatol 2004; 31: 50813.
  • 26
    Nowlin NS, Brick JE, Weaver DJ, Wilson DA, Judd HL, Lu JK, et al. Impotence in scleroderma. Ann Intern Med 1986; 104: 7948.
  • 27
    Simeon CP, Fonollosa V, Vilardell M, Ordi J, Solans R, Lima J. Impotence and Peyronie's disease in systemic sclerosis [letter]. Clin Exp Rheumatol 1994; 12: 464.
  • 28
    Lally EV, Jimenez SA. Impotence in progressively systemic sclerosis. Ann Intern Med 1981; 95: 1503.
  • 29
    Lally EV, Jimenez SA, Kaplan SR. Progressive systemic sclerosis: mode of presentation, rapidly progressive disease course, and mortality based on an analysis of 91 patients. Semin Arthritis Rheum 1988; 18: 113.
  • 30
    Ouimet JM, Pope J. Erectile dysfunction in men with scleroderma. Scleroderma Care Res 2004; 2: 149.
  • 31
    Benrud-Larson LM, Haythornthwaite JA, Heinberg LJ, Boling C, Reed J, White B, et al. The impact of pain and symptoms of depression in scleroderma. Pain 2002; 95: 26775.
  • 32
    Haythornthwaite JA, Heinberg LJ, McGuire L. Psychologic factors in scleroderma. Rheum Dis Clin North Am 2003; 29: 42739.
  • 33
    Matsuura E, Ohta A, Kanegae F, Haruda Y, Ushiyama O, Koarada S, et al. Frequency and analysis of factors closely associated with the development of depressive symptoms in patients with scleroderma. J Rheumatol 2003; 30: 17827.
  • 34
    Roca RP, Wigley FM, White B. Depressive symptoms associated with scleroderma. Arthritis Rheum 1996; 39: 103540.
  • 35
    Angelopoulos NV, Drosos AA, Moutsopoulos HM. Psychiatric symptoms associated with scleroderma. Psychother Psychosom 2001; 70: 14550.
  • 36
    Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001; 358: 111923.
  • 37
    Denton CP, Black CM, for the 351 and BREATHE-1 Study Groups. Bosentan for scleroderma associated pulmonary arterial hypertension: a subgroup analysis of two placebo controlled trials [abstract]. Arthritis Rheum 2003; 48 Suppl 9: S456.
  • 38
    Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomized, controlled trial. Ann Intern Med 2000; 132: 42534.
  • 39
    Oudiz RJ, Schilz RJ, Barst RJ, Galie N, Rich S, Rubin LJ, et al, and the Treprostinil Study Group. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest 2004; 126: 4207.
  • 40
    Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin LJ, et al, and the Aerosolized Iloprost Randomized Study Group. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347: 3229.

APPENDIX A:

  1. Top of page
  2. Introduction
  3. Subjects and Methods
  4. Results
  5. Discussion
  6. REFERENCES
  7. APPENDIX A:
  8. APPENDIX B:
Table  . QUESTION #13 FROM THE “TREATMENT PRACTICES IN SCLERODERMA” STUDY QUESTIONNAIRE
13. How often do you use the following for worsening interstitial lung disease in scleroderma?
 NeverRarelyOccasionallyFrequently
Methotrexate
D-penicillamine
Azathioprine (Imuran)
Anti-TNF drugs
High-dose steroids
Cytoxan (cyclophosphamide)
Bosentan (Tracleer)
Other: 

APPENDIX B:

  1. Top of page
  2. Introduction
  3. Subjects and Methods
  4. Results
  5. Discussion
  6. REFERENCES
  7. APPENDIX A:
  8. APPENDIX B:
Table  . QUESTION #19 FROM THE “TREATMENT PRACTICES IN SCLERODERMA” STUDY QUESTIONNAIRE
19. What percentage of your scleroderma patients have the following clinically relevant conditions:
a) Small bowel overgrowth?□ <5%□ 5–10%□ 11–20%□ 21–30%□ >30%
b) Interstitial lung disease?□ <5%□ 5–10%□ 11–20%□ 21–30%□ >30%
c) Renal crisis?□ <5%□ 5–10%□ 11–20%□ 21–30%□ >30%
d) Pulmonary hypertension?□ <5%□ 5–10%□ 11–20%□ 21–30%□ >30%
e) Cardiomyopathy?□ <5%□ 5–10%□ 11–20%□ 21–30%□ >30%
f) Inflammatory arthritis?□ <5%□ 5–10%□ 11–20%□ 21–30%□ >30%
g) Depression?□ <5%□ 5–10%□ 11–20%□ 21–30%□ >30%
h) Erectile dysfunction?□ <5%□ 5–10%□ 11–20%□ 21–30%□ >30%
i) Other: □ <5%□ 5–10%□ 11–20%□ 21–30%□ >30%